Home/Pipeline/AIM-001

AIM-001

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

Aloe Therapeutics

About Aloe Therapeutics

Aloe Therapeutics is a private, preclinical-stage biotech based in San Diego, founded in 2018, focused on overcoming resistance to checkpoint inhibitors in solid tumors. Its core technology, AIM-001, is an off-the-shelf, non-engineered cell therapy delivered locally to bait a potent, systemic immune response by mimicking transplant rejection biology. The company aims to improve response rates and durability for the majority of solid tumor patients who do not benefit from current immunotherapies, with a product designed for ease of integration into standard surgical and biopsy procedures.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed